Ozan Alkan

Ozan Alkan currently serves as Head of Research at iECURE, inc., starting October 2023. Previously, Ozan held the role of Vice President and Head of Molecular Biology at Carmine Therapeutics from May 2021 to May 2023, focusing on new genetic medicines based on red blood cell extracellular vesicles. Ozan's experience includes senior positions in molecular biology at Tidal Therapeutics and Generation Bio, specializing in mRNA delivery and non-viral gene therapy. Ozan also contributed significantly to DNA damage repair pathway research at Merrimack, held a project manager position at the Broad Institute, and completed postdoctoral work at Stanford University. Ozan earned a PhD in Cell Biology from The University of Freiburg, with additional education at the Massachusetts Institute of Technology and Harvard Medical School.